Cost‐effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus‐related hepatocellular carcinoma treated with sorafenib. Issue 12 (29th November 2016)

• Record Type: Journal Article
• Authors: Zhang, Pengfei; Yang, Yu; Wen, Feng; Wheeler, John; Fu, Ping; Li, Qiu
• Is Part Of: Journal of gastroenterology and hepatology. Volume 31:Issue 12(2016:Dec.)
• Page Start: 1978
• Page End: 1985
• Publication Date: 2016-11-29
• Subjects: cost‐effectiveness -- antiviral therapy -- hepatitis B virus -- hepatocellular carcinoma -- sorafenib; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.13425
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background and Aim: Antiviral therapy has been demonstrated to significantly improve the survival in patients with advanced hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC). The aim of the study was to investigate the cost‐effectiveness of antiviral therapy in patients with advanced HBV‐related HCC treated with sorafenib. Methods: To conduct the analysis, a Markov model comprising three health states (progression‐free survival, progressive disease, and death) was created. The efficacy data were derived from medical records. Cost data were collected based on the Chinese national drug prices. Utility data came from the previously published studies. One‐way sensitivity analyses as well as probabilistic sensitivity analyses were performed to explore model uncertainties. Results: In the base‐case analysis, addition of antiviral therapy to sorafenib generated an effectiveness of 0.68 quality‐adjusted life years (QALYs) at a cost of $25 026.04, while sorafenib monotherapy gained an effectiveness of 0.42 QALYs at a cost of $20 249.64. The incremental cost‐effectiveness ratio (ICER) was $18 370.77/QALY for antiviral therapy group versus non‐antiviral therapy group. On the other hand, the ICER between the two groups in patients with high or low HBV‐DNA load, with or without cirrhosis, normal or elevated alanine aminotransferase/aspartate aminotransferase were $16 613.97/QALY, $19 774.16/QALY, $14 587.66/QALY, $19 873.84/QALY, $17 947.07/QALY, and $18 785.58/QALY, respectively. Conclusions: Based on the cost‐effectiveness threshold ($20 301.00/QALY in China), addition of antiviral therapy to sorafenib is considered to be a cost‐effective option compared with sorafenib monotherapy in patients with advanced HBV‐related HCC in China from the patient's perspective.